Skip to main content
Retour
Watch Compare

Insight Molecular Diagnostics Inc.

Qualité des données : 100%
IMDX
NASDAQ Manufacturing Chemicals
3,42 €
▼ 0,19 € (-5,26%)
6 months return
—
Momentum
Neutral
5Y revenue growth
-14,89%

Croissance

Revenue Growth (5Y)
-14,89%
En dessous de la moyenne du secteur (1,82%)
Revenue (1Y)115,58%
Earnings (1Y)N/A
FCF Growth (3Y)N/A

Qualité

Return on Equity
N/A
ROIC-100,79%
Net Margin-1238,52%
Op. Margin-1260,76%

Sécurité

Debt / Equity
N/A
Current Ratio2,79
Interest Coverage-469,03

Valorisation

PE (TTM)
-1,98
En dessous de la moyenne du secteur (-1,49)
P/B RatioN/A
EV/EBITDAN/A
Dividend YieldN/A

Quick Summary

Key Takeaways

Short bullets derived from reported financials—not the AI summary above.

Revenue declined -14,89% annually over 5 years
Negative free cash flow of -25,37 M
Revenue growth is accelerating — 1Y growth exceeds 5Y average by 130,47%
Capital intensive — 78,55% of revenue goes to capex

Price History

Tendances Financières

Objectif de Cours des Analystes

3 analystes
Buy
+143.7%
upside to target
Actuel
3,42 €
Consensus Target
8,33 €
4,00 €
Bas
12,00 €
Haut
Prévisions
BPA Prévisionnel
-0,87 €
CA Est.
8,17 M

Surprises de Résultats

EPS
Reported Estimate Forecast
Next: Q1 2026 · EPS Est: -0,26 € · Rev Est: 227 500,0
Q12025 Q22025 Q32025 Q42025 Q1 '26 Q2 '26
Reported -0,23 € -0,30 € -0,23 € -0,72 € — —
Estimate -0,25 € -0,24 € -0,24 € -0,24 € -0,26 € -0,25 €
Surprise +9,84% -25,00% +2,75% -203,16% — —

Growth

Rev 5Y: -14,89% · Earnings 1Y: N/A
Revenue Growth (1Y) 115,58% Revenue Growth (3Y) 64,25%
Earnings Growth (1Y) N/A Earnings Growth (3Y) N/A
Revenue Growth (5Y) -14,89% Earnings Growth (5Y) N/A

Profitability

ROE: N/A · Net Margin: -1238,52%
Revenue (TTM) 4,06 M Net Income (TTM) -50,22 M
ROE N/A ROA -106,34%
Gross Margin 56,67% Operating Margin -1260,76%
Net Margin -1238,52% Free Cash Flow (TTM) -25,37 M
ROIC -100,79% FCF Growth (3Y) N/A

Safety

D/E: N/A · Current: 2,79
Debt / Equity N/A Current Ratio 2,79
Interest Coverage -469,03 Asset Turnover 0,09
Working Capital 13,73 M Tangible Book Value -23,80 M

Dividends

Yield: N/A · Payout: N/A
Dividend Yield N/A Payout Ratio N/A
Dividend Growth (3Y) N/A Dividend Growth (5Y) N/A
Consecutive Div Years N/A

Valuation

P/E: -1,98 · EV/EBITDA: N/A
P/E Ratio -1,98 Forward P/E N/A
P/B Ratio N/A P/S Ratio 24,51
PEG Ratio N/A Forward PEG N/A
EV/EBITDA N/A Fwd EV/EBITDA N/A
Forward P/S 12,16 Fwd Earnings Yield N/A
FCF Yield -25,52%
Market Cap 99,40 M Enterprise Value 80,71 M

Per Share

EPS: -1,65 · FCF/Share: -0,79
EPS (Diluted TTM) -1,65 Revenue / Share 0,13
FCF / Share -0,79 OCF / Share -0,69
EPS CAGR (1Y) N/A EPS CAGR (5Y) N/A
EPS CAGR (10Y) N/A

Efficiency

FCF Conv: 50,51% · CapEx/Rev: 78,55%
CapEx / Revenue 78,55% FCF Conversion 50,51%
SBC-Adj. FCF -27,32 M Growth Momentum 130,47

Income Statement

Annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Revenue 4,06 M 1,88 M 1,50 M 958 000,0 7,73 M
Net Income -50,22 M -60,66 M -27,78 M -72,90 M -64,10 M
EPS (Diluted) -1,65 -4,66 -3,75 — —
Gross Profit 2,30 M 740 000,0 413 000,0 -18 000,0 188 000,0
Operating Income -51,12 M -61,04 M -25,14 M -18,00 M -74,21 M
EBITDA — — — — —
R&D Expenses 15,90 M 9,84 M 9,29 M 7,30 M 13,63 M
SG&A Expenses — — — — —
D&A 2,20 M 1,56 M 1,59 M 1,50 M 844 000,0
Interest Expense -109 000,0 -84 000,0 -52 000,0 -77 000,0 -209 000,0
Income Tax 0,0 0,0 — -9,26 M -9,26 M

Balance Sheet

Annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Total Assets 25,76 M 35,08 M 74,89 M 100,09 M 159,56 M
Total Liabilities 57,22 M 47,36 M 49,30 M 60,50 M 94,35 M
Shareholders' Equity -31,46 M -12,27 M 20,47 M 34,29 M 65,22 M
Total Debt — — — — —
Cash & Equivalents 11,58 M 8,64 M 9,43 M 19,99 M 35,61 M
Current Assets 15,31 M 11,76 M 10,70 M 25,54 M 39,14 M
Current Liabilities 12,08 M 7,28 M 7,19 M 12,11 M 14,12 M

Comparaison Sectorielle

vs médiane du secteur Manufacturing (1605 pairs)
Métrique Action Médiane du Secteur
P/E -2,0 -1,5
P/B — 1,6
ROE % — -54,5
Net Margin % -1238,5 -41,5
Rev Growth 5Y % -14,9 1,8
D/E — 0,3